Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

Approvals Action
PBAC-backed drug ticked

Posted 7 June 2021

The spinal muscular atrophy market, which has been the focus of much activity lately, has continued in that vein with the registration of Roche's Evrysdi.

Evrysdi was recommended for PBS listing in March with the PBAC saying it should be cost-minimised against Biogen's Spinraza. It is yet to appear on the PBS with the Medicine Status Website showing the Department of Health is still waiting for "required documentation" to be lodged.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options